Title : Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.

Pub. Date : 2013 Sep

PMID : 23784744






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Naproxen and cromolyn as new glycogen synthase kinase 3beta inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. Cromolyn Sodium glycogen synthase kinase 3 beta Mus musculus
2 Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties. Cromolyn Sodium glycogen synthase kinase 3 beta Mus musculus
3 Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties. Cromolyn Sodium glycogen synthase kinase 3 beta Mus musculus
4 Both drugs not only were optimally fitted within a GSK-3beta binding pocket via several attractive interactions with key amino acids but also exhibited potent in vitro enzymatic inhibitory activities of IC50 1.5 and 2.0 microM for naproxen and cromolyn, respectively. Cromolyn Sodium glycogen synthase kinase 3 beta Mus musculus
5 It can be concluded that naproxen and cromolyn are novel GSK-3beta inhibitors and can help in management of diabetes and obesity. Cromolyn Sodium glycogen synthase kinase 3 beta Mus musculus